Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Polymorphic genes and markers from HLA-B (centromeric to HLA-C) to the corneodesmosin (CDSN) gene (telomeric to HLA-C) were genotyped in order to determine their contribution to the susceptibility to psoriasis.
|
16297191 |
2005 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The pattern of axial disease was influenced significantly by the presence of skin psoriasis and <i>HLA-B*27</i>.
|
27913376 |
2017 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Other MHC-I-opathies include ankylosing spondylitis and HLA-B*27-associated spondyloarthropathies and HLA-C*0602-associated skin psoriasis.
|
28898393 |
2018 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Comparing PsA and psoriasis, the prevalence of HLA-B*27 and HLA-Cw*12 were more common in PsA patients, while the prevalence of HLA-DR*07 was higher in those with psoriasis (p < 0.05).
|
18381784 |
2008 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
HLA-B*58 was associated with GT and HLA-B*57 was possibly associated with psoriasis.
|
25176018 |
2015 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
A close association between psoriasis and HLA-B 13 an B 17 was found in both discordant and concordant pairs.
|
6179364 |
1982 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
By applying the transmission/disequilibrium test (TDT) and parametric linkage analysis, we found evidence for linkage of psoriasis to HLA-C, -B, -DR, and -DQ, with HLA-B and -C yielding the most-significant results.
|
9634500 |
1998 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Although there are many similarities among AS patients possessing HLA-B*27 versus those lacking this gene, the former group has a younger age of onset, a shorter delay in diagnosis, a better clinical response to tumor necrosis factor inhibitors, a greater familial occurrence, a greater risk for occurrence of acute anterior uveitis, and a lower risk for occurrence of psoriasis and IBD.
|
28386763 |
2017 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Articles were selected, following predefined criteria, from case-control studies on the association between psoriasis and HLA-B published between 1 January 1972 and 11 November 2012, and included in the PubMed and ISI Web of Knowledge databases.
|
23600465 |
2013 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The following HLA alleles were over-transmitted to PsA compared with psoriasis: HLA-C*12 (p=0.005), HLA-B*38 (p=0.04), HLA-B*39 (p=0.03), HLA-B*27 (p=0.002).
|
22586163 |
2012 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Of note, these 'MHC-I-opathies' show a differential immunopathology, probably reflecting antigenic differences within target tissues: HLA-B(*)51 is linked to ocular and mucocutaneous disease but not gut involvement, and HLA-C(*)0602 is linked to type I psoriasis but not scalp or nail disease.
|
26526644 |
2015 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The following information was recorded in web-based case report forms: demographic, clinical and radiographic data; physical examination findings, including tender and swollen joint counts (TJC and SJC); nail and skin involvement; Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate (DAS 28-ESR); Bath Ankylosing Spondylitis Disease Activity Index (BASDAI); Maastricht Ankylosing Spondylitis Enthesitis Score (MASES); Psoriasis Area Severity Index (PASI); Bath Ankylosing Spondylitis Radiology Index for the spine (BASRI-s); Health Assessment Questionnaire (HAQ); Bath Ankylosing Spondylitis Functional Index (BASFI); Health Assessment Questionnaire for the spondyloarthropathies (HAQ-s); Psoriatic arthritis quality of Life scale (PsAQoL); Short Form 36 (SF-36); Hospital Anxiety Depression Scale (HADS); Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F); and Fibromyalgia Rapid Screening Tool (FiRST) scores.
|
31773391 |
2020 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
High-need patients with psoriasis had a lower frequency of HLA-Cw*06 but a higher prevalence of HLA-B*46 compared with general patients with psoriasis in our population.
|
21985130 |
2012 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Comparison of HLA-B and HLA-C regions in psoriatic arthritis with those in psoriasis without joint involvement demonstrates significant differences, such that psoriatic arthritis cannot be viewed simply as a subset of genetically homogeneous psoriasis.
|
19232079 |
2009 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
A detailed analysis of HLA-B in both populations demonstrated that HLA-B*57 was associated with an increased risk of psoriasis and HLA-B*40 a decreased risk, independently of HLA-Cw*0602 and the C6orf10 locus, suggesting the potential pathogenic involvement of HLA-B.
|
19680446 |
2009 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that IL12B plays a fundamental role on the pathophysiology of TAK in combination with HLA-B(∗)52:01 and that common autoimmune mechanisms underlie the pathology of TAK and other autoimmune disorders such as psoriasis and inflammatory bowel diseases in which IL12B is involved as a genetic predisposing factor.
|
23830516 |
2013 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The MICA-129 methionine (Met) allele, particularly Met/Met homozygosity, was strongly associated with both cutaneous psoriasis (PsC) and psoriatic arthritis (PsA) independently of HLA-B and HLA-C in Toronto patients, and was also associated with PsA in St. John's patients, but with no additional effect of Met/Met homozygosity.
|
23611695 |
2013 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The following haplotypes were independently associated with PsA compared to PsC: HLA-B*18-C*07 (OR 10.1, p=0.004), HLA-B*27-C*01 (OR 41.1, p<0.0001), HLA-B*27-C*02 (OR 19.9, p<0.0001), HLA-B*38-C*12 (OR 2.9, p=0.01), HLA-B*08-C*07 (OR 2.6, p=0.004) and HLA-B*57-C*06 (OR 0.5, p=0.03).
|
21900282 |
2012 |
Psoriasis
|
0.200 |
Biomarker
|
disease |
BEFREE |
After controlling for the age of psoriasis onset no association of PsA to HLA-C*06:02 (p=0.07) was observed; instead, the most significant association was to amino acid at position 97 of HLA-B (p=1.54×10<sup>-9</sup>) where the presence of asparagine or serine residue increased PsA risk.
|
28821532 |
2017 |
Psoriasis
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.
|
23143594 |
2012 |
Psoriasis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
By comparisons of empirical risk figures for psoriasis in first-degree relatives of concordant as compared with discordant MZ probands and HLA-B 13 and/or HLA-B 17 positive MZ probands compared with MZ probands lacking these antigens, no clue to the presence of genetic heterogeneity was found.
|
6204483 |
1984 |
Psoriasis
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.
|
20953190 |
2010 |
Psoriasis
|
0.200 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2.
|
20953188 |
2010 |
Psoriasis
|
0.200 |
GeneticVariation
|
disease |
GWASDB |
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.
|
23143594 |
2012 |
Psoriasis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Moreover, we need to determine allele-specific effects of ERAP1 variants in the context of HLA-B*51 and HLA-Cw*6, which are associated with Behçet's disease and psoriasis, respectively.
|
26002027 |
2015 |